Core Viewpoint - Citigroup is anticipating a pretax loss of approximately $1.2 billion from a sale in the fourth quarter of this year [1] Group 1 - The expected loss is significant and indicates potential challenges in the company's financial performance for the upcoming quarter [1]

Key Takeaways Arkema will divest impact modifiers and processing aids to Praana; the assets generated 44 million in 2024.ARKAY's sale covers global MBS copolymers and European and Asian AIMPA from its Coating Solutions segment.Arkema will sell the Vlissingen, Netherlands, plant with 50 employees, and keep the Mobile plant.Arkema S.A. (ARKAY) has announced a proposed sale of part of its impact modifiers business and processing aids to the Indian group Praana to streamline and increase focus on its strategic ...

Core Viewpoint - Sapporo Holdings is planning to divest its real estate business to a consortium led by KKR for 400 billion yen ($2.6 billion) to focus on its core beer brewing operations [1][2][3] Group 1: Company Strategy - Sapporo aims to concentrate management resources on its primary operations, specifically its beer business, by negotiating the sale of its real estate assets [2] - The funds generated from the sale will be reinvested into the beer business and other areas to enhance corporate value [3] Group 2: Real Estate Business Details - The real estate holdings include the Yebisu Garden Place in Tokyo, which features the Yebisu Brewery along with dining and shopping options [2] - The investment consortium, which includes KKR and PAG, plans to increase property profits by attracting new tenants and considering future redevelopment of Yebisu Garden Place [3] Group 3: Market Reaction - Following the announcement of the sale, Sapporo's shares increased by 2.86% [4]

Core Viewpoint - MT Højgaard Holding is selling its last business activity in Greenland, the technical contracting and service company Arssarnerit, with the sale expected to complete in Q2 2026, pending competition authority approval [1]. Group 1: Sale Details - The buyer, VVS & El Firmaet A/S, will acquire all activities of Arssarnerit, including operating assets, inventory, ongoing projects, employees, and guarantees for completed projects up to a certain limit [2]. - The sale price corresponds to the book value of the sold assets and liabilities [2]. Group 2: Strategic Focus - Prior to this agreement, MT Højgaard Holding divested its HVAC service business and all activities outside Nuuk to concentrate Arssarnerit on its core technical contracting activities in the Nuuk area [3]. - The sale of Arssarnerit marks the final step in winding down MT Højgaard Holding's international operations, which began in October 2023, leaving only minor operating assets in Greenland [4]. Group 3: Financial Outlook - The agreement does not impact MT Højgaard Holding's 2025 outlook, which remains unchanged with expected revenue between DKK 10-10.5 billion and an operating profit (EBIT) of DKK 400-450 million [5].

Core Insights - The coffee maker is selling a 60% stake in the business to Boyu Capital [1] Company Summary - The transaction involves a significant equity stake, indicating a strategic partnership or investment [1] Industry Context - The move reflects ongoing trends in the coffee industry, where investments and partnerships are becoming increasingly common to enhance growth and market presence [1]

Core Viewpoint - Starbucks Corp. is selling a 60% stake in its operations in China, indicating a significant strategic shift in its business model in the region [1] Company Summary - The sale of a 60% piece of its operations in China suggests that Starbucks is reassessing its market presence and operational strategy in one of its key international markets [1]

Core Insights - Carlyle and Boyu Capital are leading bidders for a majority stake in Starbucks' operations in mainland China, with the business valued at $4 billion excluding royalties [1][2] - Starbucks is reviewing offers from five bidders, with a decision expected by the end of October 2025 [2] - The total transaction value, including partner investment and future royalties, is projected to exceed $10 billion [3] Group 1: Bidding Process - Five companies submitted binding proposals in early October 2025 [1] - Bidders may form a consortium, with Starbucks potentially retaining up to 49% ownership [4] - The evaluation criteria for bidders include their ability to improve the supply chain and maintain local partnerships, which may favor Chinese firms [4] Group 2: Financial Performance - Starbucks' China division has faced challenges from lower-priced competitors like Luckin Coffee, leading to price reductions on some beverages [2] - For Q3 FY25, Starbucks reported net earnings of $558.3 million, a 47% decline compared to the same period in FY24 [5] - As of June 2025, Starbucks operated 7,828 stores in mainland China, while Luckin Coffee had approximately 26,000 outlets [5] Group 3: Market Context - The divestment comes amid declining revenue for Starbucks in China, attributed to weaker same-store sales [4] - The interest in the sale process reflects confidence in the long-term growth potential of Starbucks in the Chinese market [3]

Core Insights - Fairfax Financial Holdings has signed a term sheet with Eurobank Ergasias Services and Holdings for the acquisition of an 80% stake in Eurolife's life insurance business for €813 million ($944 million) in cash [1] - Post-transaction, Eurobank will fully own Eurolife's life insurance operations, while Fairfax retains an 80% stake in Eurolife's property and casualty (P&C) insurance business [1] - Fairfax will acquire a 45% equity interest in ERB Asfalistiki for €59 million, with an option to purchase the remaining 55% stake in the future [2] - The completion of these transactions is expected in the first quarter of 2026, subject to standard closing conditions [2] - Alexandros Sarrigeorgiou will be appointed as executive chairman of the Board of Directors for Eurolife's general insurance business, with Vassilis Nikiforakis as CEO and managing director [3] - This deal is anticipated to enhance Fairfax's presence in the Greek insurance industry [3] - Fairfax CEO Prem Watsa expressed satisfaction in maintaining focus on P&C insurance while benefiting from Eurolife's life insurance success [4] - The life insurance business of Eurolife has performed well under Sarrigeorgiou's leadership, and continued success is expected under Eurobank's ownership [5]

Core Viewpoint - Polaris Inc plans to divest its majority stake in Indian Motorcycle to focus on more profitable growth areas, with the transaction expected to close in Q1 2026 [2][3]. Group 1: Transaction Details - Polaris has entered into a definitive agreement to sell a majority stake in Indian Motorcycle to Carolwood LP, an independent private equity firm [2]. - The separation is projected to increase Polaris' annualized adjusted EBITDA by approximately $50 million and adjusted earnings by about $1 per share [3]. - Polaris will retain a small equity position in Indian Motorcycle post-transaction, with Mike Kennedy appointed as CEO of the new independent entity [4]. Group 2: Financial Performance - Polaris anticipates third-quarter sales to be at the high end of its guidance range of $1.6 billion to $1.8 billion, with adjusted earnings expected between 31 cents and 41 cents per share, significantly higher than previous expectations [5]. - Following the announcement, Polaris shares rose by 12.45% in after-hours trading, reaching $69 [6].

Core Viewpoint - Elutia has agreed to sell its EluPro and CanGaroo bioenvelopes to Boston Scientific for $88 million in cash, allowing the company to focus on its development and commercialization efforts without diluting shareholder value [1][4]. Group 1: Transaction Details - The sale of EluPro and CanGaroo bioenvelopes is valued at $88 million in cash [1]. - The transaction is expected to close in the fourth quarter of 2025, pending customary closing conditions [4]. - BofA Securities is serving as the financial advisor to Elutia for this transaction [4]. Group 2: Product Information - The EluPro BioEnvelope is designed to facilitate the regeneration of healthy, vascularized tissue while preventing post-operative complications [1]. - The CanGaroo Envelope aims to create a conducive environment for tissue healing by regulating the biological response to injury [2]. - Both bioenvelopes are part of Elutia's proprietary drug-eluting biologics platform, which has demonstrated effectiveness at scale [2]. Group 3: Financial Implications - The proceeds from the sale will fully fund the advancement and commercialization of Elutia's NXT-41 and NXT-41x products [4]. - The sale is expected to enhance Elutia's financial position by allowing the company to eliminate outstanding debt and resolve litigation related to its previously divested orthobiologics business [3]. Group 4: Market Focus - Elutia plans to focus its resources on advancing its SimpliDerm franchise and its drug-eluting pipeline within the US breast reconstruction market, which is valued at $1.5 billion [4]. - The company has secured seven national group purchasing organization contracts and over 160 value analysis committee approvals for EluPro, indicating strong market acceptance [3].